PNC Reports 8.13% Stake and Sole Voting Power in Cadrenal Therapeutics
PNC Financial Services reports beneficial ownership of 233,219 shares of Cadrenal Therapeutics common stock, representing 8.13% of the class, as of June 30, 2026. PNC Bank, National Association holds sole voting and sole dispositive power over the shares, indicating a significant institutional position in Cadrenal Therapeutics’ governance.